NAFLD-EASD Study Group - Spring Virtual Meeting

3 - 4 June, 2021 5:00 PM (Rome)

"Sexual Dimorphism And FGF Signaling In NAFLD"

Thursday, June 3, 5:00-7:00 PM (Italian time)

• PPARα as a sexually dimorphic drug target in NAFLD Hervé GUILLOU (Toxalim, INRAE, Toulouse, France)
• Sex-discriminating factor in hepatic metabolism Adriana MAGGI (Università di Milano, Italy)

Friday, June 4, 5:00-7:00pm (Italian time)

• The rationale for the use of fibroblast growth factors for the treatment of Nash, Arun Sanyal (Virginia Commonwealth University, Richmond, VA, USA)
• Fibroblast growth factors for NASH treatment Stephen HARRISON (Pinnacle Clinical Research, San Antonio, TX, USA)
• FGF19 and FGF21 for the Treatment of NASH—Two Sides of a Coin? Birgitte ANDERSEN (NovoNordisk, Copenhagen, DK)

The preliminary program can be download here

Click the links to register: NAFLD-EASD Study Group - Virtual Spring Meeting - June 3-4, 2021 – 5:00 PM (Rome)

Disclaimer: Neither Eli Lilly nor Gilead Sciences Europe Ltd. had any input into the content of the materials and presentations used at this event

For further information contact the EGIR-EASD Secretariat